|
|
 Previous Article | Table of Contents | Next Article 
Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia
with Yttrium-90-labeled anti-Tac [see comments]
TA Waldmann, JD White, JA Carrasquillo, JC Reynolds, CH Paik, OA Gansow, MW Brechbiel, ES Jaffe, TA Fleisher and CK Goldman
Metabolism Branch, National Cancer Institute, National Institutes of
Health, Bethesda, MD 20892, USA.
Adult T-cell leukemia (ATL) is a malignancy of mature lymphocytes caused by
the retrovirus human T-cell lymphotropic virus-I. It is an aggressive
leukemia with a median survival time of 9 months; no chemotherapy regimen
appears successful in inducing long-term disease- free survival. The
scientific basis of the present study is that ATL cells express
high-affinity interleukin-2 receptors identified by the anti-Tac monoclonal
antibody, whereas normal resting cells do not. To exploit this difference,
we administered anti-Tac armed with Yttrium-90 (90Y) to 18 patients with
ATL initially (first 9 patients) in a phase I dose-escalation trial and
subsequently (second group of 9 patients) in a phase II trial involving a
uniform 10-mCi dose of 90Y-labeled anti- Tac. Patients undergoing a
remission were permitted to receive up to eight additional doses. At the 5-
to 15-mCi doses used, 9 of 16 evaluable patients responded to 90Y anti-Tac
with a partial (7 patients) or complete (2 patients) remission. The
responses observed represent improved efficacy in terms of length of
remission when compared with previous results with unmodified anti-Tac.
Clinically meaningful (> or = grade 3) toxicity was largely limited to
the hematopoietic system. In conclusion, radioimmunotherapy with 90Y anti-
Tac directed toward the IL-2R expressed on ATL cells may provide a useful
approach for treatment of this aggressive malignancy.
Volume 86,
Issue 11,
pp. 4063-4075,
12/01/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. K. Gopal, J. M. Pagel, J. R. Fromm, S. Wilbur, and O. W. Press
131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma
Blood,
June 4, 2009;
113(23):
5905 - 5910.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Pagel, N. Orgun, D. K. Hamlin, D. S. Wilbur, T. A. Gooley, A. K. Gopal, S. I. Park, D. J. Green, Y. Lin, and O. W. Press
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
Blood,
May 14, 2009;
113(20):
4903 - 4913.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Pise-Masison, M. Radonovich, K. Dohoney, J. C. Morris, D. O'Mahony, M.-J. Lee, J. Trepel, T. A. Waldmann, J. E. Janik, and J. N. Brady
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability
Blood,
April 23, 2009;
113(17):
4016 - 4026.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Khaibullina, B.-S. Jang, H. Sun, N. Le, S. Yu, V. Frenkel, J. A. Carrasquillo, I. Pastan, K. C.P. Li, and C. H. Paik
Pulsed High-Intensity Focused Ultrasound Enhances Uptake of Radiolabeled Monoclonal Antibody to Human Epidermoid Tumor in Nude Mice
J. Nucl. Med.,
February 1, 2008;
49(2):
295 - 302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G P Taylor
Molecular aspects of HTLV-I infection and adult T-cell leukaemia/lymphoma
J. Clin. Pathol.,
December 1, 2007;
60(12):
1392 - 1396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Yao, H. Patel, K. Garmestani, Z. Zhang, V. S. Talanov, P. S. Plascjak, C. K. Goldman, J. E. Janik, M. W. Brechbiel, et al.
Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1
PNAS,
May 15, 2007;
104(20):
8444 - 8448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Ramos, P. Ruiz Jr, L. Ratner, I. M. Reis, C. Brites, C. Pedroso, G. E. Byrne Jr, N. L. Toomey, V. Andela, E. W. Harhaj, et al.
IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma
Blood,
April 1, 2007;
109(7):
3060 - 3068.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Yao, Z. Zhang, K. Garmestani, V. S. Talanov, P. S. Plascjak, S. Yu, H.-S. Kim, C. K. Goldman, C. H. Paik, et al.
The Anti-CD25 Monoclonal Antibody 7G7/B6, Armed with the {alpha}-Emitter 211At, Provides Effective Radioimmunotherapy for a Murine Model of Leukemia
Cancer Res.,
August 15, 2006;
66(16):
8227 - 8232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Zhang, M. Zhang, K. Garmestani, V. S. Talanov, P. S. Plascjak, B. Beck, C. Goldman, M. W. Brechbiel, and T. A. Waldmann
Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25
Blood,
August 1, 2006;
108(3):
1007 - 1012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Datta, M. Bellon, U. Sinha-Datta, A. Bazarbachi, Y. Lepelletier, D. Canioni, T. A. Waldmann, O. Hermine, and C. Nicot
Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence
Blood,
August 1, 2006;
108(3):
1021 - 1029.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Yao, Z. Zhang, K. Garmestani, C. K. Goldman, J. V. Ravetch, J. Janik, M. W. Brechbiel, and T. A. Waldmann
Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors
Blood,
July 15, 2006;
108(2):
705 - 710.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Pagel, Y. Lin, N. Hedin, A. Pantelias, D. Axworthy, D. Stone, D. K. Hamlin, D. S. Wilbur, and O. W. Press
Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas
Blood,
July 1, 2006;
108(1):
328 - 336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Pagel, F. R. Appelbaum, J. F. Eary, J. Rajendran, D. R. Fisher, T. Gooley, K. Ruffner, E. Nemecek, E. Sickle, L. Durack, et al.
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
Blood,
March 1, 2006;
107(5):
2184 - 2191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ravandi and S. O'Brien
Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
December 1, 2005;
80(12):
1660 - 1674.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. A. Vallera, M. W. Brechbiel, L. J. Burns, A. Panoskaltsis-Mortari, K. E. Dusenbery, D. R. Clohisy, and E. S. Vitetta
Radioimmunotherapy of CD22-Expressing Daudi Tumors in Nude Mice with a 90Y-Labeled Anti-CD22 Monoclonal Antibody
Clin. Cancer Res.,
November 1, 2005;
11(21):
7920 - 7928.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Richman, S. J. DeNardo, R. T. O'Donnell, A. Yuan, S. Shen, D. S. Goldstein, J. M. Tuscano, T. Wun, H. K. Chew, P. N. Lara, et al.
High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody
Clin. Cancer Res.,
August 15, 2005;
11(16):
5920 - 5927.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Zhang, C. K. Goldman, J. Janik, and T. A. Waldmann
Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody
Blood,
February 1, 2005;
105(3):
1231 - 1236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ise, H. Maeda, K. Santora, L. Xiang, R. J. Kreitman, I. Pastan, and S. Nagata
Immunoglobulin Superfamily Receptor Translocation Associated 2 Protein on Lymphoma Cell Lines and Hairy Cell Leukemia Cells Detected by Novel Monoclonal Antibodies
Clin. Cancer Res.,
January 1, 2005;
11(1):
87 - 96.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Savage
Aggressive Peripheral T-Cell Lymphomas (Specified and Unspecified Types)
Hematology,
January 1, 2005;
2005(1):
267 - 277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Zhang, K. Garmestani, C. K. Goldman, J. V. Ravetch, M. W. Brechbiel, J. A. Carrasquillo, and T. A. Waldmann
Activating Fc Receptors Are Required for Antitumor Efficacy of the Antibodies Directed toward CD25 in a Murine Model of Adult T-Cell Leukemia
Cancer Res.,
August 15, 2004;
64(16):
5825 - 5829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Yao, M. Zhang, K. Garmestani, D. B. Axworthy, R. W. Mallett, A. R. Fritzberg, L. J. Theodore, P. S. Plascjak, W. C. Eckelman, T. A. Waldmann, et al.
Pretargeted {alpha} Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid-Biotin
Clin. Cancer Res.,
May 1, 2004;
10(9):
3137 - 3146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. C. Moura, Y. Lepelletier, B. Arnulf, P. England, C. Baude, C. Beaumont, A. Bazarbachi, M. Benhamou, R. C. Monteiro, and O. Hermine
A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients
Blood,
March 1, 2004;
103(5):
1838 - 1845.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M. Foss, S. L. Aquino, and J. A. Ferry
Case 10-2003 - A 72-Year-Old Man with Rapidly Progressive Leukemia, Rash, and Multiorgan Failure
N. Engl. J. Med.,
March 27, 2003;
348(13):
1267 - 1275.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Zhang, K. Garmestani, J. Schultz, D. B. Axworthy, C. K. Goldman, M. W. Brechbiel, J. A. Carrasquillo, and T. A. Waldmann
Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts
PNAS,
February 18, 2003;
100(4):
1891 - 1895.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.C. Church
Clinical advances in therapies targeting the interleukin-2 receptor
QJM,
February 1, 2003;
96(2):
91 - 102.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Yao, K. Garmestani, D. B. Axworthy, Z. Zhang, R. W. Mallett, L. J. Theodore, C. K. Goldman, M. W. Brechbiel, J. A. Carrasquillo, et al.
Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha -emitting radionuclide, bismuth 213
Blood,
June 17, 2002;
100(1):
208 - 216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. El-Sabban, R. A. Merhi, H. A. Haidar, B. Arnulf, H. Khoury, J. Basbous, J. Nijmeh, H. de The, O. Hermine, and A. Bazarbachi
Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells
Blood,
May 1, 2002;
99(9):
3383 - 3389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kobayashi, K. Shirakawa, S. Kawamoto, T. Saga, N. Sato, A. Hiraga, I. Watanabe, Y. Heike, K. Togashi, J. Konishi, et al.
Rapid Accumulation and Internalization of Radiolabeled Herceptin in an Inflammatory Breast Cancer Xenograft with Vasculogenic Mimicry Predicted by the Contrast-enhanced Dynamic MRI with the Macromolecular Contrast Agent G6-(1B4M-Gd)256
Cancer Res.,
February 1, 2002;
62(3):
860 - 866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. W. Press, J. P. Leonard, B. Coiffier, R. Levy, and J. Timmerman
Immunotherapy of Non-Hodgkin's Lymphomas
Hematology,
January 1, 2001;
2001(1):
221 - 240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Phillips, B. Herring, L. A. Wilson, M. S. Rickford, M. Zhang, C. K. Goldman, J. Y. Tso, and T. A. Waldmann
IL-2R{{alpha}}-Directed Monoclonal Antibodies Provide Effective Therapy in a Murine Model of Adult T-Cell Leukemia by a Mechanism other than Blockade of IL-2/IL-2R{{alpha}} Interaction
Cancer Res.,
December 1, 2000;
60(24):
6977 - 6984.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. C Morris and T. A Waldmann
Advances in interleukin 2 receptor targeted treatment
Ann Rheum Dis,
November 1, 2000;
59(90001):
i109 - 114.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. W. Press
Emerging Immunotherapies for Non-Hodgkin Lymphomas: The Tortoise Approaches the Finish Line
Ann Intern Med,
June 6, 2000;
132(11):
916 - 918.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Pai-Scherf, J. A. Carrasquillo, C. Paik, O. Gansow, M. Whatley, D. Pearson, K. Webber, M. Hamilton, C. Allegra, M. Brechbiel, et al.
Imaging and Phase I Study of 111In- and 90Y-labeled Anti-LewisY Monoclonal Antibody B3
Clin. Cancer Res.,
May 1, 2000;
6(5):
1720 - 1730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Waldmann, R. Levy, and B. S. Coller
Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy
Hematology,
January 1, 2000;
2000(1):
394 - 408.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Franchini, R. F. Ambinder, and M. Barry
Viral Disease in Hematology
Hematology,
January 1, 2000;
2000(1):
409 - 423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Chaudhry, J. A. Carrasquillo, I. L. Avis, N. Shuke, J. C. Reynolds, R. Bartholomew, S. M. Larson, F. Cuttitta, B. E. Johnson, and J. L. Mulshine
Phase I and Imaging Trial of a Monoclonal Antibody Directed against Gastrin-releasing Peptide in Patients with Lung Cancer
Clin. Cancer Res.,
November 1, 1999;
5(11):
3385 - 3393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Pavlinkova, B. J. M. Booth, S. K. Batra, and D. Colcher
Radioimmunotherapy of Human Colon Cancer Xenografts Using a Dimeric Single-Chain Fv Antibody Construct
Clin. Cancer Res.,
September 1, 1999;
5(9):
2613 - 2619.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Matthews, F. R. Appelbaum, J. F. Eary, D. R. Fisher, L. D. Durack, T. E. Hui, P. J. Martin, D. Mitchell, O. W. Press, R. Storb, et al.
Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome
Blood,
August 15, 1999;
94(4):
1237 - 1247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Manns, W. J. Miley, D. Waters, B. Hanchard, G. Wharfe, B. Cranston, E. Williams, and W. A. Blattner
Prognostic Significance of Quantitative Viral Markers in Adult T-Cell Leukemia/Lymphoma
Blood,
July 1, 1999;
94(1):
372 - 373.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Junghans, J. A. Carrasquillo, and T. A. Waldmann
Impact of antigenemia on the bioactivity of infused anti-Tac antibody: Implications for dose selection in antibody immunotherapies
PNAS,
February 17, 1998;
95(4):
1752 - 1757.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
